Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer

20260 citationsJournal Articlegold Open Access

Authors

Helen R. Davies · Cancer Research UK

Daniella Black · Cancer Research UK

Anders Kvist · Lund University

K. Sigurjónsdóttir · Lund University

Ana Bosch · Lund University

Ramsay Bowden · Cancer Research UK

Y. Memari · Cancer Research UK

Abstract

ERpHER2n HRD tumors show features of aggressive disease, but do not display a distinct transcriptional or DNA methylation profile that clearly differentiates them from HR-proficient tumors. Though numbers are limited, we present early evidence that HRD stratification by WGS could impact therapeutic strategies, as HRD BCs trended to poorer outcomes when not treated with chemotherapy.

Topics & Keywords

PARP inhibition in cancer therapy BRCA gene mutations in cancer DNA Repair Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Communications Medicine

Volume 6, Issue 1, pp. 118-118

DOI: 10.1038/s43856-026-01385-0

Field-Weighted Citation Impact: 0.00